Clinicopathologic correlations of genomic gains and losses in follicular lymphoma

Journal of Clinical Oncology

Volumn 20, Issue 23, 2002, Pages 4523-4530

  Viardot, Andreas ^a   Möller, Peter ^a   Högel, Josef ^a   Werner, Kirsten ^a   Mechtersheimer, Gunhild ^a   Ho, Anthony D ^a   Ott, German ^a   Barth, Thomas F E ^a   Siebert, Reiner ^a   Gesk, Stefan ^a   Schlegelberger, Brigitte ^a   Döhner, Hartmut ^a   Bentz, Martin ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CANCER GENETICS; CHROMOSOME 12Q; CHROMOSOME 18Q; CHROMOSOME 6Q; CHROMOSOME 7P; CHROMOSOME 7Q; CHROMOSOME ABERRATION; CHROMOSOME ARM; CHROMOSOME BAND; CHROMOSOME XP; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; FOLLICULAR LYMPHOMA; GENE LOSS; GENETIC RISK; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KARYOTYPE; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 12; CHROMOSOMES, HUMAN, PAIR 18; CHROMOSOMES, HUMAN, PAIR 6; CHROMOSOMES, HUMAN, PAIR 7; DNA, NEOPLASM; FEMALE; FROZEN SECTIONS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; L-LACTATE DEHYDROGENASE; LYMPHOMA, FOLLICULAR; MALE; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TRANSLOCATION, GENETIC; X CHROMOSOME;

EID: 0036894041     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.12.006     Document Type: Article

References (50)

1. Yunis JJ, Frizzera G, Oken MM, et al: Multiple recurrent genomic defects in follicular lymphoma: A possible model for cancer. N Engl J Med 316:79-84, 1987
2. Horning SJ: Follicular lymphoma: Have we made any progress? Ann Oncol 37:23-27, 2000 (suppl 7)
3. Gallagher CJ, Gregory WM, Jones AE, et al: Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol 4:1470-1480, 1986
4. Litam P, Swan F, Cabanillas F, et al: Prognostic value of serum beta-2-mikroglobulin in low grade lymphoma. Ann Intern Med 114:855-860, 1991
5. Soubeyran P, Eghbali H, Bonichon F, et al: Low-grade follicular lymphoma: Analysis of prognosis in a series of 281 patients. Eur J Cancer 27:1606-1613, 1991
6. Coiffier B, Bastion Y, Berger F, et al: Prognostic factors in follicular lymphomas. Semin Oncol 20:89-95, 1993
7. Bastion Y, Berger F, Bryon PA, et al: Follicular lymphomas: Assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol 2:123-129, 1991
8. Development of a predictive model for aggressive lymphoma: The International NHL Prognostic Factors Project. N Engl J Med 329:987-994, 1993
9. Lopez-Guillermo A, Montserrat E, Bosch F, et al: Applicability of the international index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 12:1343-1348, 1994
10. Federico M, Vitolo U, Zinzani PL, et al: Prognosis of follicular lymphoma: A predictive model based on a retrospective analysis of 987 cases. Blood 95:783-789, 2000
11. Bloomfield CD, Lawrence D, Byrd JC, et al: Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173-4179, 1998
12. Döhner H, Stilgenbauer S, Benner A, et al: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 28:1910-1916, 2000
13. Hoelzer D, Gokbuget N: New approaches to acute lymphoblastic leukemia in adults: Where do we go? Semin Oncol 27:540-559, 2000
14. Tilly H, Rossi A, Stamatoullas A, et al: Prognostic value of chromosomal aberrations in follicular lymphomas. Blood 84:1043-1049, 1994
15. Kallioniemi A, Kallioniemi. P, Sudar D: Comparative genomic hybridization for molecular analysis of solid tumors. Science 258:818-821, 1992
16. Lichter P, Joos S, Bentz M, et al: Comparative genomic hybridization: Uses and limitations. Semin Hematol 37:348-357, 2000
17. Harris NL, Jaffe ES, Diebold J, et al: The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting - Airlie House, Virginia, November 1997. Hematol J 1:53-66, 2000
18. Jaffe ES, Harris NL, Stein H, et al (eds): Pathology and Genetics of Tumours of the Hematopoietic and Lymphoid Systems: World Health Organization Classification of Tumours. Lyon, France, IARC Press, 2001, pp 162-167
19. Schlegelberger B, Zwingers T, Harder S, et al: Clinicopathogenetic significance of chromosomal abnormalities in patients with blastic peripheral B-cell lymphoma. Blood 94:1-8, 1999
20. Taniwaki M, Silverman G, Nishida K, et al: Translocations and amplification of the BCL2 gene are detected in interphase nuclei of non-Hodgkin's lymphoma by in situ hybridization with yeast artificial chromosome clones. Blood 86:1481-1486, 1995
21. Gribben JG, Freedman AS, Woo SD, et al: All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation after treatment. Blood 78:3275-3280, 1991
22. Lichter P, Bentz M, Joos S: Detection of chromosomal aberrations by means of molecular cytogenetics: Painting of chromosomes and chromosomal subregions and comparative genomic hybridization. Methods Enzymol 254:334-359, 1995
23. Du Manoir S, Schrock E, Bentz M, et al: Quantitative analysis of comparative genomic hybridization. Cytometry 19:27-41, 1995
24. Kaplan EL, Meier P: Non-parametric estimation from incomplete observation. J Am Stat Assoc 47:457-481, 1958
25. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc (Ser A) 135:185-192, 1972
26. Cox DR: Regression models and life tables. J R Stat Soc (Ser B) 34:187-220, 1972
27. Bentz M, Werner CA, Döhner H, et al: High incidence of chromosomal imbalances and gene amplifications in the classical follicular variant of follicle center lymphoma. Blood 88:1437-1444, 1996
28. Viardot A, Martin-Subero JI, Siebert R, et al: Detection of secondary aberrations in follicle center cell lymphoma: Assessment of the reliability of comparative genomic hybridization (CGH) and standard chromosome analysis. Leukemia 15:177-183, 2001
29. Johannson B, Mertens F, Mitelman F: Cytogenetic evolution patterns in non-Hodgkin's lymphomas. Blood 86:3905-3914, 1995
30. Horsman DE, Connors JM, Pantzar T, et al: Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). Genes Chromosom Cancer 30:375-382, 2001
31. Avet-Loiseau H, Vigier M, Moreau A, et al: Comparative genomic hybridization detects genomic abnormalities in 80% of follicular lymphomas. Br J Hematol 97:119-122, 1997
32. Barth TFE, Döhner H, Werner CA, et al: Characteristic patterns of chromosomal aberrations in primary large B-cell lymphomas of the gastrointestinal tract. Blood 91:4321-4330, 1998
33. Beá S, Ribas M, Hernandez JM, et al: Increased numbers of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 93:4365-4374, 1999
34. Monni O, Joensuu H, Franssila K, et al: BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell Lymphoma. Blood 90:1168-1174, 1997
35. Hough RE, Goepel JR, Alcock HE, et al: Copy number gain at 12q12-14 may be important in the transformation from follicular lymphoma to diffuse large B-cell lymphoma. Br J Cancer 84:499-503, 2001
36. Mohamed AN, Palutke M, Eisenberg L, et al: Chromosomal analysis of 52 cases of follicular lymphoma with the t(14;18), including blastic/blastoid variant. Cancer Genet Cytogenet 126:45-51, 2001
37. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000
38. Offit K, Wong G, Phillipa DA, et al: Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphomas: Clinical correlations. Blood 77:1508-1515, 1991
39. Whang-Peng J, Knutsen T, Jaffe ES, et al: Sequential analysis of 43 patients with non-Hodgkin's lymphoma: Clinical correlations with cytogenetic histologic, immunophenotyping, and molecular studies. Blood 85:203-216, 1995
40. Gaidano G, Hauptschein RS, Parsa NZ, et al: Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma. Blood 80:1781-1787, 1992
41. Offit K, Parsa NZ, Gaidano G, et al: 6q deletions define distinct clinico-pathologic subsets of non-Hodgkin's lymphoma. Blood 82:2157-2162, 1993
42. Hauptschein RS, Gaidano G, Rao PH, et al: An apparent interlocus gene conversion-like event at a putative tumor suppressor gene locus on human chromosome 6q27 in a Burkitt's lymphoma cell line. DNA Res 7:261-272, 2000
43. Hauptschein RS, Gamberi B, Pulivarthi RH: Cloning and mapping of human chromosome 6q26-q27 deleted in B-cell non-Hodgkin lymphoma and multiple tumor types. Genomics 50:170-186, 1998
44. Abdollahi A, Bao R, Hamilton TC: LOT1 is a growth suppressor gene down-regulated by the epidermal growth factor receptor ligands and encodes a nuclear zinc-finger protein. Oncogene 18:6477-6487, 1999
45. Bilanges B, Varrault A, Basyuk E, et al: Loss of expression of the candidate tumor suppressor gene ZAC in breast cancer cell lines and primary tumors. Oncogene 18:3979-3988, 1999
46. Garcia M, Derocq D, Freiss G, et al: Activation of estrogen receptor transfected into a receptor negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc Natl Acad Sci U S A 89:11538-11542, 1992
47. Menasce LP, White GRM, Harrison CJ, et al: Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. Genomics 17:263-264, 1993
48. Issa JP, Zehnbauer BA, Civin CA, et al: The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Res 56:973-977, 1996
49. Acquati F, Morelli C, Cinquetti R, et al: Cloning and characterization of a senescence inducing and class II tumor suppressor gene in ovarian carcinoma at chromosome region 6q27. Oncogene 20:980-988, 2001
50. Seute A, Sinn HP, Schlenk RF, et al: Clinical relevance of genomic aberrations in homogenously treated high-risk stage II/III breast cancer patients. Int J Cancer 93:80-84, 2001